PolyPeptide Group Announces Plans to Expand GMP Manufacturing Facilities
TORRANCE, CA, August 1, 2005 - In response to growing demand for therapeutic peptides, PolyPeptide Group has announced plans to substantially increase its manufacturing capabilities in both the US and Europe.
The expansion will take place at two of PolyPeptide Group' GMP manufacturing facilities: Torrance, CA and Malmo, Sweden. The result will be a doubling of the manufacturing capacity in Torrance and substantial increases in the capacity in Malmo.
The expansion plans for both facilities focus mainly on increased capacity for solid-phase peptide manufacturing. The increase in solid-phase capacity in the Torrance and Malmo facilities serves to complement the large solution-phase synthesis capabilities already present at the PolyPeptide Group facilities in Malmo, Sweden and Hillerød, Denmark.
The decision to expand the facilities in response to the increasing demand from both biotech and pharmaceutical customers for experienced large-scale GMP peptide manufacturing will help to maintain PolyPeptide Group' leading position in this exciting market. The combination of technical know-how, state-of-the-art production facilities and comprehensive regulatory support that PolyPeptide Group provides their customers is considered a critical advantage in the competitive drug development arena, and has helped to sustain double digit growth rates for the company. Both biotech and large pharmaceutical companies have benefited greatly from the experience and knowledge of PolyPeptide Group in the development of their clinical peptide therapeutic compounds.
The new facilities are planned to begin production in 2006.
PolyPeptide Laboratories A/S